Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06521567 · ClinicalTrials.gov registry record · Phase 1

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

A Phase 1 study of Melanoma and Hodgkin Lymphoma, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 1
Development phase
83
Enrollment target
20
Study locations

NCT06521567 is a Phase 1 study of Melanoma and Hodgkin Lymphoma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 83 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06521567, a Phase 1 study of Melanoma and Hodgkin Lymphoma, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
83 participants
Enrollment target
20
Study locations

Study Summary

The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants

Conditions Studied

Melanoma Hodgkin Lymphoma Osteosarcoma Ependymoma Hepatocellular Carcinoma (HCC) Hepatoblastoma Glioblastoma Multiforme (GBM) Diffuse Intrinsic Pontine Glioma (DIPG) High and Low Grade Glioma Hepatic Tumors

Interventions

  • DRUG Dostarlimab
  • DRUG Cobolimab

Study Locations (20)

Other

  • GSK Investigational Site - Brno
  • GSK Investigational Site - Phaha 5
  • GSK Investigational Site - Copenhagen
  • GSK Investigational Site - Bordeaux
  • GSK Investigational Site - Lyon
  • GSK Investigational Site - Paris
  • GSK Investigational Site - Strasbourg
  • GSK Investigational Site - Villejuif
  • GSK Investigational Site - Bologna
  • GSK Investigational Site - Naples
  • GSK Investigational Site - Barcelona
  • GSK Investigational Site - Madrid
  • GSK Investigational Site - Madrid
  • GSK Investigational Site - Valencia

California

  • GSK Investigational Site - Los Angeles

Iowa

  • GSK Investigational Site - Iowa City

New Jersey

  • GSK Investigational Site - Hackensack

Ohio

  • GSK Investigational Site - Cincinnati

Rhode Island

  • GSK Investigational Site - Providence

Wisconsin

  • GSK Investigational Site - Madison

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2025-03-06
Est. Completion 2026-10-13
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06521567

The ClinicalTrials.gov registry entry for NCT06521567 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Dostarlimab is the first listed.

NCT06521567 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Iowa.

Frequently Asked Questions

What is clinical trial NCT06521567 about?

NCT06521567 is a clinical study titled "A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer". The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adul...

What is the current status of trial NCT06521567?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2025-03-06. Estimated completion is 2026-10-13.

What conditions does trial NCT06521567 study?

This clinical trial studies the following conditions: Melanoma, Hodgkin Lymphoma, Osteosarcoma, Ependymoma, Hepatocellular Carcinoma (HCC).

What interventions are being tested in trial NCT06521567?

The interventions under investigation include: Dostarlimab (DRUG), Cobolimab (DRUG).

Who is sponsoring clinical trial NCT06521567?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06521567 being conducted?

This trial has 20 study locations across California, Iowa, New Jersey, Ohio, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Hodgkin Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.